Form 4: Castle Biosciences CEO Sells Shares Under 10b5-1 Plan

Castle Biosciences' President and CEO, Derek J. Maetzold, sold 1,339 shares of common stock for approximately $40.03 per share under a pre-arranged 10b5-1 plan.

Summary

• Derek J. Maetzold, President & CEO and Director of Castle Biosciences Inc. (CSTL), sold 1,339 shares of common stock.
• The transaction occurred on December 4, 2025, at a weighted-average price of $40.03 per share, with individual trades ranging from $40.00 to $40.11.
• This sale was executed pursuant to a Rule 10b5-1 plan adopted by Mr. Maetzold on May 8, 2025.
• Following this transaction, Mr. Maetzold directly beneficially owns 37,547 shares of common stock.
• He also indirectly beneficially owns shares through various trusts, including 52,923 shares via The Maetzold Descendants 2020 Trust, 44,986 shares via Derek Maetzold 2020 Irrevocable Trust, 14,463 shares across four Maetzold 2018 Remainder Trusts, and 148,900 shares across three DJM Grantor Retained Annuity Trusts.

Sentiment

Score: 5

Explanation: The sale of shares by the CEO is generally a neutral to slightly negative event. However, the fact that it was executed under a pre-arranged 10b5-1 plan mitigates concerns about opportunistic selling, making the overall sentiment neutral.

Positives

• The sale was conducted under a pre-arranged Rule 10b5-1 plan, indicating it was not a reactive or opportunistic sale based on new, non-public information.

Negatives

• An insider sale, even if pre-planned, can sometimes be perceived negatively by investors as it reduces the insider's direct stake in the company.

Future Outlook

No forward-looking statements or guidance are provided in this Form 4 filing.

Industry Context

This filing is a routine insider transaction report and does not provide information relevant to broader industry trends or competitors.

Related Party Transactions

• The indirect beneficial ownership through various trusts (e.g., The Maetzold Descendants 2020 Trust, Derek Maetzold 2020 Irrevocable Trust, DJM Grantor Retained Annuity Trusts) represents holdings by related parties.

Stakeholder Impact

• Shareholders might interpret the CEO's sale of shares differently; some may view it as a routine diversification or liquidity event, while others might perceive it as a lack of confidence, despite the 10b5-1 plan.

Key Dates

Recommendation

This Form 4 filing reports a routine, pre-planned insider sale of a relatively small number of shares by the CEO. It does not provide new information about the company's operational performance, financial health, or strategic direction that would warrant a change in investment recommendation. Investors should consider this as a standard liquidity event for the insider, not a signal for a buy or sell decision based solely on this filing.

Keywords

Castle Biosciences, CSTL, Derek Maetzold, Insider Sale, Form 4, Stock Transaction, 10b5-1 Plan, CEO, Director